Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds

Andreas Charidimou(National Hospital for Neurology and Neurosurgery), Toshio Imaizumi(National Hospital for Neurology and Neurosurgery), Solène Moulin(National Hospital for Neurology and Neurosurgery), Alexandro Biffi(National Hospital for Neurology and Neurosurgery), Neshika Samarasekera(National Hospital for Neurology and Neurosurgery), Yusuke Yakushiji(National Hospital for Neurology and Neurosurgery), André Peeters(National Hospital for Neurology and Neurosurgery), Yves Vandermeeren(National Hospital for Neurology and Neurosurgery), Patrice Laloux(National Hospital for Neurology and Neurosurgery), Jean‐Claude Baron(National Hospital for Neurology and Neurosurgery), Mar Hernández‐Guillamón(National Hospital for Neurology and Neurosurgery), Joan Montaner(National Hospital for Neurology and Neurosurgery), Barbara Casolla(National Hospital for Neurology and Neurosurgery), Simone M. Gregoire(National Hospital for Neurology and Neurosurgery), Dong‐Wha Kang(National Hospital for Neurology and Neurosurgery), Jong Seung Kim(National Hospital for Neurology and Neurosurgery), Hiromitsu Naka(National Hospital for Neurology and Neurosurgery), Eric E. Smith(National Hospital for Neurology and Neurosurgery), Anand Viswanathan(National Hospital for Neurology and Neurosurgery), Hans Rolf Jäger(National Hospital for Neurology and Neurosurgery), Rustam Al‐Shahi Salman(National Hospital for Neurology and Neurosurgery), Steven M. Greenberg(National Hospital for Neurology and Neurosurgery), Charlotte Cordonnier(National Hospital for Neurology and Neurosurgery), David J. Werring(National Hospital for Neurology and Neurosurgery)
Neurology
July 27, 2017
Cited by 255Open Access
Full Text

Abstract

<h3>Objective:</h3> We evaluated recurrent intracerebral hemorrhage (ICH) risk in ICH survivors, stratified by the presence, distribution, and number of cerebral microbleeds (CMBs) on MRI (i.e., the presumed causal underlying small vessel disease and its severity). <h3>Methods:</h3> This was a meta-analysis of prospective cohorts following ICH, with blood-sensitive brain MRI soon after ICH. We estimated annualized recurrent symptomatic ICH rates for each study and compared pooled odds ratios (ORs) of recurrent ICH by CMB presence/absence and presumed etiology based on CMB distribution (strictly lobar CMBs related to probable or possible cerebral amyloid angiopathy [CAA] vs non-CAA) and burden (1, 2–4, 5–10, and &gt;10 CMBs), using random effects models. <h3>Results:</h3> We pooled data from 10 studies including 1,306 patients: 325 with CAA-related and 981 CAA-unrelated ICH. The annual recurrent ICH risk was higher in CAA-related ICH vs CAA-unrelated ICH (7.4%, 95% confidence interval [CI] 3.2–12.6 vs 1.1%, 95% CI 0.5–1.7 per year, respectively; <i>p</i> = 0.01). In CAA-related ICH, multiple baseline CMBs (versus none) were associated with ICH recurrence during follow-up (range 1–3 years): OR 3.1 (95% CI 1.4–6.8; <i>p</i> = 0.006), 4.3 (95% CI 1.8–10.3; <i>p</i> = 0.001), and 3.4 (95% CI 1.4–8.3; <i>p</i> = 0.007) for 2–4, 5–10, and &gt;10 CMBs, respectively. In CAA-unrelated ICH, only &gt;10 CMBs (versus none) were associated with recurrent ICH (OR 5.6, 95% CI 2.1–15; <i>p</i> = 0.001). The presence of 1 CMB (versus none) was not associated with recurrent ICH in CAA-related or CAA-unrelated cohorts. <h3>Conclusions:</h3> CMB burden and distribution on MRI identify subgroups of ICH survivors with higher ICH recurrence risk, which may help to predict ICH prognosis with relevance for clinical practice and treatment trials.


Related Papers

No related papers found

Powered by citation graph analysis